Life Science

• Represented Merck in its 100% acquisition of OncoImmune, a Chinese pharmaceutical company specialized in developing drugs for COVID-19

• Represented Merck in its acquisition of Antelliq Group, a market leader in digital animal identification, traceability, and monitoring

• Represented Elanco on in its strategic in-licensing transaction with a leading Chinese biotech firm, involving an innovative animal health candidate

• Represented a U.S. biotech in the cross-border structuring and establishment of a NewCo specifically for the development of next-generation CAR-T therapies

• Represented Phrontline Biopharma in matters concerning its ADC product, covering multi-regional commercialization rights

• Represented a Chinese biotech in its complex cross-border merger with a prominent German pharmaceutical group

• Represented Hua MedTech and its shareholders in sales of 100% shares to Genesis MedTech, a pharmaceutical company specialized in cardiology, oncology, peripheral vascular, and neurovascular interventional products

• Represented Qilu Pharmaceutical in one of its major pharmaceutical subsidiaries' Series B financing and in-licensing transaction with Lily. 

• Represented 6 Dimensions in its proposed investment in a medical device company

• Represented AZ-CICC Fund in its investment in Series B financing of a medical device company

• Represented Eiger in the proposed establishment of a NewCo with a PRC pharmaceutical company

• Represented Sanofi-aventis in its formation of a healthcare products joint venture with China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.

M&A, Private Equity, and General Corporate

• Represented Beijing Capital in its SGD 500 million sales of certain assets in Singapore to Seche, a French listed company

• Represented Horizon Robotic in its establishment of a joint venture with Volkswagen with EUR 2.4 billion investment

• Represented Horizon Robotic in its Series D financing and convertible bonds issuance

• Represented a SOE in its proposed USD 1 billion acquisition of certain semiconductor assets from a leading U.S. company  

• Represented SWIFT in its establishment of a joint venture with a PRC entity

• Represented Tencent in its investment in a LoT company's Series D financing

• Advised a Hollywood studio on its distribution of the following films in China: Alita: Battle Angel, X-Men: Dark Phoenix, Bohemian Rhapsody, and Once Upon a Deadpool

• Advised a Hollywood studio on its joint production of a film with a PRC film production company

• Advised Village Roadshow on its establishment of a theme park in China

• Advised a GP on its negotiation of a co-production and funding agreement with its limited partners

• Advised Tencent on its negotiation of a Sponsored Event Agreement in relation to a mobile game

• Advised a foreign government entity on China's new energy vehicle policies

• Advised Breitling on its asset acquisition in China

• Advised a top fashion brand in its establishment of a joint venture with a PRC garment company

• Advised a state-owned investment company on its proposed acquisition of 15% shares in a Lebanese bank

• Advised an investment vehicle of Tsinghua University on its acquisition of several real estate properties in Milan

• Advised China-LAC Co-operation Fund on its investment in a hydroelectric power station corporation in Brazil

• Advised a subsidiary of Textron on its proposed formation of a pilot training joint venture with a state-owned aviation enterprise

• Advised GE Technology Development, Inc. on the establishment of an energy storage joint venture with a wholly-owned subsidiary of Hong Kong listed Chaowei Power Holdings Limited

• Advised Jiangxi Copper on its proposed acquisition of a state-owned copper mine in the Republic of Congo

• Advised Tsinghua Unigroup and Insight Investment on Insight's USD 368.8 million acquisition of NYSE-listed Xueda Education Group

Capital Market

• Represented underwriters led by Citigroup and UBS in the USD 127.2 million IPO and NYSE listing of American Depository Shares of Bitauto Holdings Ltd.

• Represented underwriters led by CICC, Goldman Sachs, J.P. Morgan, Morgan Stanley, Credit Suisse, and BOCI in the USD 1.7 billion IPO, Rule 144A/Regulation S offering, and Hong Kong Stock Exchange listing of H Shares of Changsha Zoomlion Heavy Industry Science and Technology Development Co. Ltd.

• Represented Underwriters led by Morgan Stanley in the USD 67.2 million IPO and NYSE listing of American Depositary Shares of SYSWIN Inc.

• Represented Morgan Stanley in the USD 70 million IPO and Hong Kong Stock Exchange listing of SPT Energy Group Inc.

• Represented Morgan Stanley and Goldman Sachs in the proposed IPO and NYSE listing of American Depositary Shares of Lashou Holdings Ltd.

• Advised Sinopec Shanghai Petrochemical Company Limited on its SEC compliance matters